IRCT201710241556N100RecruitingPhase 2
Vortioxetine as adjunctive treatment of negative symptoms in patients with schizophrenia: a double blind and placebo controlled trial
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Enrollment
- 50
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to 60 years (—)
- Sex
- All
Inclusion Criteria
- •1-Diagnosis of Schizophrenia based on DSM-5 criteria; 2- Age between 18-60; 3-Chronic Schizophrenia- duration of the disorder more than 2 years; 4-Minimum score of 20 in negative sub score. 5-being stable on risperidone for the last 2 months. Exclusion criteria:1-Any serious medical or neurological problem; 2- IQ less than 70; 3- Substance dependence during the last 6 months(except for nicotine and caffeine); 4- Score on HDRS less than 14 5-receiving ECT during the last 3 months ; 6-Acute or chronic systemic diseases; 7- History of neurosurgery; 8- History of head trauma.
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Completed
Phase 2
Duloxetine in patients with schizophreniaschizophreniaschizophrenia.IRCT201506201556N77Tehran University of Medical Sciences50
Completed
Phase 3
Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive DisorderMajor Depressive DisorderNCT02279953H. Lundbeck A/S151
Not yet recruiting
Phase 2
A randomized placebo-controlled trial of vortioxetine for obsessive-compulsive disorderCTRI/2023/12/060748Indican Council of Medical Research
Recruiting
Not Applicable
Relationship between the effects of vortioxetine and sleep EEG findings in depressioDepressionJPRN-UMIN000047036ihon University Itabashi Hospital30
Unknown
Phase 2
Vortioxetine add-on Treatment Improves the Symptoms in Patients With Bipolar DepressionBipolar Disorder DepressionNCT03598868Seoul National University Hospital100